Mesenchymal stem cells (MSCs) hold immense promise for the field of regenerative medicine and cell-based therapy. Found in many tissues including bone marrow, adipose tissue and umbilical cord blood, MSCs have the unique ability to differentiate into a variety of cell types and promote tissue repair through modulation of the immune system. Scientists across the world are conducting extensive research to fully unlock the therapeutic potential of these versatile cells. This article discusses the properties of MSCs, current research and future applications.
What are MSCs?
MSCs are multipotent stem cells that can differentiate into cell types such as osteoblasts, chondrocytes and adipocytes. They were first identified in the 1970s in bone marrow and since then have been found in other tissues as well. MSCs make up a very small fraction (0.001-0.01%) of the total bone marrow mononuclear cell population. Isolation and expansion of these rare cells is a prerequisite for any potential clinical application. Typically MSCs are identified through specific cell surface markers like CD73, CD90 and CD105 and are negative for hematopoietic markers.
Immunomodulatory Properties
One of the most intriguing properties of MSCs is their ability to suppress immune cell proliferation and action. They reduce immune responses mediated by T cells, B cells, natural killer cells and dendritic cells. This effect is partly attributed to the secretion of molecules like prostaglandin E2, indoleamine 2,3-dioxygenase, interleukin-10 and transforming growth factor-beta by the MSCs. Due to their low immunogenicity and immunomodulatory capacities, Mesenchymal stem cells show promise in treating autoimmune disorders and preventing graft-versus-host disease following allogeneic cell transplantation.
Bone and Cartilage Repair
Bone marrow derived MSCs have been extensively studied for their ability to enhance bone formation and bone healing both in vitro and in preclinical animal models. Upon appropriate stimulation, they can differentiate into osteoblasts and form new bone mineralized tissues. Similarly, when induced to differentiate into chondrocytes they aid in cartilage repair. Many clinical trials are exploring the use of MSC-based therapies for reconstructive orthopedic procedures and treatment of osteoarthritis and osteonecrosis. Adipose tissue-derived MSCs are also being investigated for cartilage regeneration due to abundant tissue availability through lipoaspiration.
Heart Disease and Stroke
Research shows that transplanted MSCs migrate to sites of injury in the heart after a myocardial infarction and promote regeneration of cardiac muscle cells and blood vessels. MSC therapy reduces infarction size and improves left ventricular function and outcomes after heart attacks in animal models. Early phase clinical trials demonstrate safety in human patients as well. MSCs may also benefit brain repair after ischemic strokes. Preclinical evidence shows enhanced angiogenesis, neurogenesis and neuroplasticity with reduced inflammation and improved motor deficits. Larger controlled clinical trials are ongoing to establish efficacy.
Diabetes and Liver Disease
The ability of MSCs to differentiate into insulin producing pancreatic beta cells has raised hopes for cell-based therapy of diabetes. While full differentiation is challenging, preclinical data shows that MSCs help preserve existing beta cells and reduce hypoxia and apoptosis in the pancreas leading to better glucose control. For end stage liver diseases, MSC transplantation supports liver regeneration through hepatocyte differentiation and immunomodulation. Transplantation of umbilical cord-derived MSCs significantly improved hepatic function and survival in animal models of fulminant hepatic failure.
Challenges and Future Directions
Despite immense therapeutic potential, there are several challenges to the clinical translation of MSC-based therapies. Key issues include development of standardized isolation and large scale expansion protocols, understanding MSC heterogeneity and potency variations, ensuring safety from tumor formation post-transplant and tracking long term cell engraftment and immunogenicity in the body. Advances in gene and molecular engineering may enhance the regenerative functions of MSCs. Combination studies utilizing scaffolds, growth factors and co-transplanted cell types could maximize repair outcomes. With further refinement, MSCs provide a promising avenue for developing safe and effective treatments across a wide range of currently incurable conditions. Several new clinical trials are planned with MSCs modified to express therapeutically relevant molecules. As our knowledge of MSC biology expands, it is very likely that these cells or their derivatives will start transforming patient care in the years to come.
Get More Insights Here
https://www.ukwebwire.com/mesenchymal-stem-cells-in-medicine/
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian